Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors

NCT03689192 is registered in ClinicalTrials.gov with Herlev Hospital as lead sponsor.

NCT NCT03689192
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03689192 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors
Lead sponsor
Herlev Hospital
Phase
Phase 1
Overall status
Completed
Start date
December 17, 2018
Completion date
January 19, 2022
Enrollment
13 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, colorectal cancer, malignant melanoma, metastatic cancer, non small cell lung cancer, ovarian cancer, squamous cell carcinoma of the head and neck, urothelial carcinoma